Abstract. In the present study, we established a new experimental model to investigate the effects of EGFR targeting by RNAi, and the synergistic actions between the Hedgehog (Hh) and EGFR signaling pathways on the proliferation and apoptosis in pancreatic cancer cells. Three human pancreatic cancer cell lines expressing EGFR shRNA were established, and gene expression inhibition was assessed in these lines using RT-PCR and western blot analysis. The effects of EGFR RNAi and Hh inhibition on cell proliferation and apoptosis were explored in vitro and in vivo. We observed that EGFR RNAi notably inhibited cell proliferation and colony formation, induced apoptosis and markedly decreased xenograft tumor growth. Furthermore, EGFR RNAi significantly enhanced cycloamine sensitivity both in vitro and in vivo, and a synergistic decrease of both AKT and ERK phosphorylation was observed. The present study demonstrates that combined inhibition of both EGFR and Hh signaling pathways could establish a more promising antitumor approach than inhibiting each singly, and that there is a possible synergistic effect for Hh and EGFR signaling pathways on ERK and AKT phosphorylation.

Introduction

Pancreatic cancer is one of the most aggressive malignancies in the world, with a poor prognosis and a high mortality rate. The overall 5-year survival rate for pancreatic cancer patients remains less than 5%. Although surgical approaches have been developed, there has been no significant improvement in survival rate over the past three decades (1), which is attributed to the high incidence of metastasis at initial diagnosis (2). Further understanding of tumorigenesis of pancreatic cancer may provide new clues for developing prevention and treatment strategies.

Epidermal growth factor receptor (EGFR) plays a key role in epithelial tumor formation. Recent studies indicated that EGFR was detectable in over 95% of pancreatic cancer patients (3), and that aberrant EGFR activation can increase pancreatic cancer cell proliferation (4). In recent years, EGFR targeting therapy has become a popular mode of comprehensive tumor treatment. However, selective targeting of EGFR was not as effective as expected, because drug resistance would develop and lead to unsatisfactory clinical effect (5-7). Therefore, it remains necessary to explore additional therapeutic combinations.

Hedgehog (Hh) signaling pathway plays an important role in pancreatic carcinogenesis. It is closely associated with pancreatic cancer occurrence and progression, and is involved in cellular proliferation and invasion in vivo and in vitro (8). Research showed that EGFR and Hh signaling pathways were upregulated in many pancreatic cancer cell lines (9,10). However, the relationship and the synergistic mechanisms between these two pathways remain unclear.

In this study, we introduced a lentiviral vector containing shRNA that targets the EGFR gene into human pancreatic cancer cells. The effects of EGFR RNAi alone or in conjunction with Hh inhibition on proliferation and apoptosis were explored both in vitro and in vivo, and the possible synergistic mechanisms for Hh and EGFR signaling pathways were further investigated.

Materials and methods

Cell line and culture conditions. The human pancreatic cancer cell lines, PANC-1, ASPC-1 and Mia PaCa-2 were generously provided by Professor Beger and Professor Kornmann of Ulm University, Germany. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Sigma, St. Louis, MO, USA) and penicillin (100 U/ml).

Establishment of pancreatic cancer cell clones expressing EGFR RNAi. The RNAi targeting human EGFR sequence
Reverse transcriptase polymerase chain reaction (RT-PCR). Total RNA from wild-type pancreatic cancer cells and clones EGFR knockdown cells was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Aliquots (1 µg) of RNA were DNase-treated and processed for first-strand cDNA synthesis using the RT-PCR Kit (Toyobo, Osaka, Japan). cDNA was amplified using a PCR thermal controller with initial denaturation at 94˚C for 5 min, followed by 30 cycles of: denaturation at 94˚C for 30 sec, annealing at 61˚C for 30 sec, extension at 72˚C for 60 sec, and a final extension step at 72˚C for 5 min. GAPDH was used for gene expression normalization. Three independent experiments were performed.

Western blot analysis. The total protein from wild-type pancreatic cancer cells and the EGFR knockdown clones (PANC-1, PANC-1-nc and PANC-1-si) were obtained using the Total Protein Extraction kit (Keygen, Nanjing, China). Total protein per sample (70 µg) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto nitrocellulose membranes, and then probed with anti-phospho-Akt, anti-Akt, anti-phospho-Erk1/2, anti-Erk1/2 (Cell Signaling Technology, Beverly, MA, USA) and anti-EGFR (Abcam, Cambridge, UK) antibodies. Three independent experiments were performed.

Colony formation assay. To assess the effect of EGFR knockdown on the colony formation ability of PANC-1, PANC-1-nc and PANC-1-si cells, each were respectively seeded onto 6-well plates at various low densities. When clones appeared, they were fixed in methanol and stained with Giemsa before they were manually counted. Three independent experiments were performed.

Cell growth assays. The MTT assay was used to assess the effect of EGFR knockdown on cell proliferation and cyclopamine sensitivity in pancreatic cancer cells. Wild-type cancer cells (PANC-1) and two transduced clones (PANC-1-nc and PANC-1-si) were cultured in 96-well plates at a density of 1.0x10⁴ cells/well for 72 h prior to the proliferation assay. To assess cyclopamine sensitivity, each cell group was seeded at a density of 1.0x10⁴ cells/well in 96-well plates, and allowed to attach for 24 h. They were then incubated in media containing the indicated concentrations (0, 0.625, 1.25, 2.5, 5.0 and 10 µmol/l) of cyclopamine for 48 h before initiation of the MTT assay. The cell growth inhibition rate (GIR) was calculated as follows: GIR = (1 - OD₉₅₀ of treated cells/OD₉₅₀ of untreated cells) x 100%. Three independent experiments were performed.

Flow cytometry analysis for apoptosis. An Annexin V-PE Apoptosis Detection kit (BD Biosciences) was used to measure apoptosis in PANC-1, PANC-1-nc and PANC-1-si cells, with or without cyclopamine treatment. The cells were seeded in 6-well plates and incubated until they were about 70% confluent. Then, the cyclopamine medium was replaced with fresh media, and the cells were incubated for 48 h before analysis. The labeled cells (1.0x10⁴/sample) were analyzed using FACScan flow cytometry (BD Biosciences) in conjunction with CellQuest software. Three independent experiments were performed.

Tumor xenografts in nude mice. All animal studies were reviewed and approved by the Ethics Committee for Animal Studies at Peking University, China. Briefly, 1.0x10⁷ cells were injected subcutaneously into the right axilla of 6-week-old female nude mice. The mice were randomized into four treatment groups according to the cells injected and paired with the following treatments: i) PANC-1-nc, or PANC-1-si plus cyclopamine (50 mg/kg, dissolved in 0.1 ml PBS, intraperitoneal injection, once every other day) (11) treatment; and ii) PANC-1-nc, or PANC-1-si plus PBS treatment groups (0.1 ml intraperitoneal injection, once every other day). The animals were monitored for tumor formation every 2 days. Tumor size was measured in two dimensions, and the volume was calculated using the equation $V = L \times W^2 \times 0.5$ (where $V$ is the volume, $L$ is the length and $W$ is the width). Four weeks later, all the mice were sacrificed, and the tumors were excised and weighed.

Immunohistochemistry analysis of xenograft tumors. Paraffin-embedded 4-µm-thick sections were prepared and analyzed by H&E staining or immunohistochemical analysis using a Cell and Tissue Staining kit according to the manufacturer's protocol (R&D Systems, Minneapolis, MN, USA). To assess the proliferative index of serial sections, Ki-67 staining assay was carried out in representative non-necrotic areas of each
tumor using a rabbit anti-human Ki-67 antibody (Abcam). Tumor cell apoptosis was evaluated using the TUNEL assay (Roche, Mannheim, Germany) and was performed as described by the manufacturer.

Statistical analysis. Quantitative data were expressed as means ± SD. Means were compared using one-way ANOVA and Student's t-test. Statistical analyses were performed using SPSS Version 13.0. Differences were considered statistically significant if P<0.05.

Results

Detection of endogenous EGFR in pancreatic cancer cell lines and the effect of cyclopamine on its expression. EGFR mRNA and protein expression were determined using RT-PCR and western blot analyses, respectively, in three pancreatic cancer cell lines (PANC-1, ASPC-1 and Mia PaCa-2). As shown in Fig. 2A, the EGFR mRNA and protein expression levels differed in the three cell lines. We then studied the effect of cyclopamine, a naturally occurring Hh pathway antagonist, on EGFR expression in these cell lines. As shown in Fig. 2B, both protein and mRNA expression levels decreased in all the three cell lines after 48 h of treatment with 5 μmol/l cyclopamine. EGFR mRNA and protein expression in PANC-1 cells was higher than in the other two cell lines (P<0.05). Therefore, we selected the PANC-1 cell line for follow-up assays in order to show EGFR inhibition more clearly.

RNAi targeting EGFR in PANC-1 pancreatic cancer cells. PANC-1 cells were transfected with either recombinant pFU-GW-RNAi lentiviral vectors that target the EGFR gene (PANC-1-si), or with negative control vectors (PANC-1-nc). The stably transfected cells were purified using FACS. RT-PCR and western blot analyses probed for EGFR expression and revealed that it was significantly downregulated in PANC-1-si transfected cells, but not in PANC-1-nc transfected cells when both were compared with untransfected cells (Fig. 3). The results indicated that the EGFR-targeting RNAi could effectively suppress EGFR gene expression in PANC-1 cells.

Combined targeting of EGFR and Hh signaling enhanced inhibition of proliferation and colony formation in PANC-1 cells. The effect of EGFR inhibition on cell growth was measured using the MTT and colony formation assays. Colony formation assay was used to assess cell survival, as shown in Fig. 4. The results indicated that the number of PANC-1-si+cyclopamine colonies was fewer than those of PANC-1-nc and PANC-1-si cells (P<0.05, Fig. 4). There was no difference in colony formation inhibition when PANC-1-nc+cyclopamine cells and PANC-1-si cells were compared (P>0.05).

Cell proliferation was analyzed using the MTT assay. Proliferation was inhibited notably for EGFR knockdown cells when combined with Hh signaling inhibition by cyclopamine in the PANC-1 cell line. As shown in Fig. 5A, cyclopamine inhibited cell growth in a dose-dependent manner. The inhibi-
EFFECTS OF EGFR AND Hh SIGNALING PATHWAYS ON PROLIFERATION AND APOPTOSIS

Figure 4. Colony formation efficiencies in different EGFR expression groups. The PANC-1-si had fewer colonies than PANC-1-nc and PANC-1 cell lines. Three independent experiments were performed. *P<0.05. The error bars in the figures represent the standard error of the mean (SEM).

Figure 5. Effects of cyclopamine on the proliferation of pancreatic cancer cells and EGFR RNAi clones. (A) Growth inhibition of PANC-1, PANC-1-nc, and PANC-1-si cells at different dosages of cyclopamine. (B) IC<sub>50</sub> of cyclopamine on PANC-1, PANC-1-nc and PANC-1-si cells. *P<0.05. The error bars in the figures represent the standard error of the mean (SEM).

Synergistic effects of EGFR and Hh signaling inhibition on apoptosis in pancreatic cancer cells. Apoptosis of cultured cells was analyzed using flow cytometry. Four different conditions were tested: PANC-1-nc, PANC-1-si, PANC-1-nc+Cyc and PANC-1-si+Cyc. As shown in Fig. 6, the prophase apoptosis percentage of the control group (PANC-1-nc) was 3.117±0.121% (P=0.001); and both the EGFR RNAi group (PANC-1-si) and the cyclophamine treatment group (PANC-1-nc+Cyc) showed a moderately increased apoptosis, compared with untreated PANC-1-nc cells (P<0.05). The prophase apoptosis percentage of the combined treatment group (PANC-1-si+Cyc) was as high as 38.97±1.237%, which was significantly higher than the EGFR knockdown (PANC-1-si, 17.62±0.602%) and the control group (PANC-1-nc, 3.117±0.121%, P<0.05). The prophase apoptosis percentage of the combined treatment group (PANC-1-si+Cyc) was significantly higher than that of the PANC-1-si and PANC-1-nc+Cyc groups (P<0.05). The results showed that EGFR downregulation might reduce the apoptosis threshold in pancreatic cancer cells, and enhanced apoptosis when combined with cyclopamine treatment.

Effects of EGFR RNAi and cyclopamine on PANC-1 xenograft growth. To investigate whether the in vitro antitumor effects of EGFR inhibition and its synergistic effects with cyclophamine could be reproduced in vivo, we established xenograft models using PANC-1-nc and PANC-1-si cells. All of the PANC-1-nc injected mice died before any measurable tumors could be histologically identified. All of the PANC-1-si injected mice developed measurable tumors one week after injection. The mice then received treatments of cyclophamine or PBS once every 48 h. The xenograft tumor size was measured once a week. As shown in Fig. 7, the tumors from PANC-1-si injected mice were significantly smaller than tumors from the control cells (PANC-1-si+PBS vs. PANC-1-nc+PBS, P<0.05). Cyclophamine treatment could inhibit xenograft tumor growth compared with PBS (PANC-1-nc+Cyc vs. PANC-1-nc+PBS, P<0.05). Furthermore, the combined treatment using EGFR RNAi and cyclophamine (PANC-1-si+Cyc) resulted in additional tumor growth inhibition (Fig. 7A). Twenty-eight days after tumor inoculation, the average tumor volume of the combined treatment was significantly decreased when
Proliferation and apoptosis in xenograft tumors. We performed the Ki-67 staining assay and the TUNEL assay to evaluate proliferation in xenografts. As shown in Fig. 8, analysis of the proliferative index for the xenograft tumors revealed that both suppression of EGFR and combined treatment with cyclopamine significantly inhibited Ki-67 immunoreactivity, compared with the control groups. Combined treatment (PANC-1-si+Cyc xenografts) showed the lowest Ki-67 immunoreactivity. Tumor cell apoptosis was also assessed using the TUNEL assay (Fig. 8A). As shown in Table I, the apoptotic index for PANC-1-si+Cyc cells was significantly higher than PANC-1-nc cells and PANC-1-si cells (P<0.05). The results indicated that inhibition of both EGFR and Hh signaling pathways may have a synergistic effect on proliferation and apoptosis.

Synergistic effects of EGFR and Hh inhibition on PI3K/Akt and Raf/MEK/ERK activation. To investigate possible mechanisms for the synergistic apoptosis effect, we analyzed the PI3K/Akt and Raf/MEK/ERK activation using western blot analysis. As shown in Fig. 9, EGFR knockdown combined with cyclopamine-mediated Hh inhibition produced a pronounced decrease in both Akt and ERK phosphorylation, when compared with PANC-1-si or PANC-1-nc+Cyc cells. Moreover, phosphorylated AKT/ERK expression in PANC-1-si+Cyc tumor groups displayed a significant reduction compared with the control group (Fig. 10).
The epidermal growth factor receptor (EGFR) belongs to a family of receptor tyrosine kinases, and plays a key role in cell proliferation, survival, migration and differentiation in epithelial tumor formation (12). EGFR is localized mainly to cell membranes and is activated by the EGF ligand (13). A recent study revealed that the overexpression or deregulation of EGFR induced rapid growth, strong invasion ability, and poor prognosis for many kinds of solid tumors, including pancreatic cancer (14).

In recent years, therapy targeting EGFR has been a popular method for comprehensive tumor treatment, which includes EGFR monoclonal antibodies and small molecular tyrosine kinase inhibitors. For example, erlotinib, an EGFR-tyrosine kinase inhibitor, has been approved by the FDA as a comprehensive treatment for advanced pancreatic cancer. However, monotherapy that targets EGFR has not been as effective as expected, and the clinical effect remains unsatisfactory. Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine as a therapeutic option. A randomized phase III trial showed that improvement in patient

---

**Table 1. Apoptotic index.**

<table>
<thead>
<tr>
<th>Cells</th>
<th>Control (NS)</th>
<th>Treatment group (cyclophosphamide)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>PANC-1-nc</td>
<td>3.85±0.52</td>
<td>12.76±2.29</td>
<td>0.003</td>
</tr>
<tr>
<td>PANC-1-si</td>
<td>14.73±1.00</td>
<td>20.87±4.38*</td>
<td>0.002</td>
</tr>
</tbody>
</table>

*The apoptotic index of PANC-1-si+Cyc cells was significantly higher than the controls (P<0.05).

---

**Figure 8.** Evaluating proliferation and apoptosis in xenograft tumors. Immunohistochemistry of serial sections using a Ki-67 antibody displayed nuclear Ki-67 immunoreactivity. As shown in (B), the highest percentage of Ki-67 positive cell was observed in the PANC-1-nc group, 75.39±1.83%, and the combination of EGFR RNAi and cyclophosphamide treatment (PANC-1-si+Cyc) revealed the lowest Ki-67 positive percentage, 13.82±0.93%, compared with the other groups, (*P<0.05). The error bars in the figures represent the standard error of the mean (SEM). There were no significant differences between the PANC-1-nc+Cyc and PANC-1-si groups. As shown in (A) apoptotic nuclei appeared in the xenografts after different treatments, as judged by TUNEL staining. The apoptotic index was measured three times. As shown in Table 1, the apoptotic index of PANC-1-si+Cyc cells was significantly higher than the controls (P<0.05). The results are expressed as the mean of three experiments (mean ± SD%, n=3).

**Figure 9.** Synergistic effect of combined EGFR RNAi and cyclophosphamide treatment on Akt and ERK activation. Total cellular proteins (70 µg) from the indicated cells were subjected to western blot analysis with antibodies directed against total or phosphorylated AKT/ERK. β-actin served as loading control. Representative results of three independent experiments are shown.
survival using erlotinib or gemcitabine singly was modest (6.24 vs. 5.91 months), while the 1-year survival rate using erlotinib combined with gemcitabine was 23 vs. 17% when combining placebo with gemcitabine, a statistically significant difference (6). Therefore, there is an urgent need to explore the crosstalk mechanism between EGFR and other signaling pathways to find a more efficient combinatory antitumor strategy.

The Hh signaling pathway contributes to pancreatic cancer occurrence and progression, and participates in maintaining the biological characteristics of pancreatic cancer stem cells (15). Upregulated Hh pathway activity has been observed in human pancreatic cancer (16,17). Inhibition of Hh signaling by cyclopamine, a smoothened antagonist, inhibited pancreatic cancer growth in vitro and in vivo, suggesting that this signaling pathway has an early and critical role in pancreatic cancer formation (18). Specifically blocking Hh signaling can inhibit cell proliferation and invasion in vivo and in vitro, and may become one of the best hopes for targeted pancreatic cancer therapy. Some scholars have demonstrated a synergy between Hh and EGFR pathways in pancreatic cancer cell lines (19). Researchers have found that sonic Hedgehog (SHH) and EGFR positivity were significantly higher in 49 pancreatic cancer specimens compared with 49 matched normal specimens, as detected by immunohistochemistry (79.6 vs. 14.3%, 73.5 vs. 16.3%, P<0.05), and SHH expression was positively correlated to EGFR expression (r=0.232, P<0.05) (9). Another study showed that there was an additive effect between anti-Hh and anti-EGFR pathways that enhanced sensitivity to anti-tumor drugs in esophageal and prostate cancer cell lines (20). Hu et al. (21) found that Hh and EGFR were overexpressed in pancreatic cancer cell lines and the antitumor effects of Iressa, a tyrosine kinase inhibitor, were enhanced by downregulation of EGFR gene expression while blocking Hh signaling with cyclopamine.

In this study, we confirmed that EGFR was expressed in pancreatic cancer cell lines, and its expression was suppressed to some extent by cyclopamine. Our results indicate that EGFR knockdown could efficiently inhibit cell proliferation, increase apoptosis, and enhance cyclopamine sensitivity in human pancreatic cancer cells. EGFR downregulation significantly lowered the apoptotic threshold and enhanced sensitivity to cyclopamine. Cyclopamine appeared to selectively induce apoptosis in tumor cells without adverse effects to normal tissues in vivo (22), which suggests cyclopamine is a promising drug for preventing pancreatic cancer progression. Compared with singly blocking EGFR expression, the addition of cyclopamine to EGFR knockdown further inhibited cell proliferation and tumor growth in both cell lines and xenografts. The combination treatment inhibited pancreatic cancer cell proliferation and colony formation, and effectively enhanced cyclopamine sensitivity in vitro. These results point to a synergistic effect between the Hh and EGFR signaling pathways in the regulation of cell proliferation and apoptosis. However, the mechanism between the two pathways remains unclear.

Two important downstream signaling pathways are controlled by EGFR. The first is the RAS-RAF-MEK-MAPK pathway, which influences gene transcription and cell proliferation. The second is the PI3K-Akt pathway, which regulates apoptosis resistance and survival signals (23,24). They might also be involved in pancreatic cancer cell resistance to EGFR-targeted therapy (25,26). In the Ras-Raf-MEK-ERK/MAPK pathway, ERK plays a dual role as a membrane protein and as a transcription factor. Activated MAPKs phosphorylate and regulate specific intranuclear transcription factors (27), thus inducing cell differentiation and proliferation that contribute to tumorigenesis and migration (28). AKT is a protooncogene, coding for a serine/threonine protein kinase (29), which is activated by phospholipid binding and activation loop phosphorylation at Thr308 by PDK1 (30,31), and by phosphorylation within the C-terminus at Ser473 (32). AKT promotes cell survival by phosphorylating and inactivating apoptosis-inducing targets, including Bad (33), forkhead transcription factors (34) and caspase-9 (35). Since ERK and AKT are closely linked to cell survival and growth, we analyzed ERK and AKT phosphorylation using western blot analysis. The result showed that combining RNAi-silenced EGFR with Hh signal inhibition produced a markedly decrease in both AKT and ERK phosphorylation in vivo and in vitro. The synergistic
effect of dual EGFR and Hh signaling inhibition on proliferation and apoptosis, as presented in this study, suggests that combined treatment is likely to be a more efficient antitumor strategy than inhibiting either signal alone.

In conclusion, our present study showed that the Hh signaling pathway is involved in regulating EGFR expression, and point to a synergistic effect of Hh and EGFR. Hh pathway inhibition enhanced the effect of selective EGFR targeting on cell proliferation, and increased apoptosis in human pancreatic cancer cells *in vivo* and *in vitro*. Silencing EGFR in combination with cyclopalmine may be a potential therapeutic strategy that significantly reduces tumor size and induces apoptosis. The synergistic mechanism of Hh and EGFR signaling pathways partly contributed to ERK and AKT phosphorylation. Although results have been encouraging, additional studies are warranted.

Acknowledgements

This research was supported by grants from the National Natural Science Foundation of China (no. 30972897 to Y.-M.Y). Thanks to Professor Ze-Bin Mao of the Department of Biochemistry and Molecular Biology in Peking University Health Science Center for his assistance and technical support.

References


19. Ruck E, Eyzaguirre A, Halsey JD, Gibson NW, Cagnoni P and IWata KK: Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 5: 2051-2059, 2006.


